About 10 % of gastric carcinoma worldwide is associated with EBV, which is defined as EBV-associated gastric carcinoma (EBVaGC). To date, EBV sequence data from EBVaGC in Guangdong, China, an endemic area of nasopharyngeal carcinoma (NPC), are not available. In the present study, two EBV genomes from EBVaGC specimens from Guangdong (designated as GDGC1 and GDGC2) were determined by next-generation sequencing, de novo assembly and joining of contigs by Sanger sequencing. In addition, we sequenced EBV from two Korean EBVaGC cell lines, YCCEL1 and SNU-719. Genomic diversity, including single nucleotide polymorphisms (SNPs) and insertions and deletions (indels), phylogenetic analysis and rates of protein evolution, was performed using bioinformatics software. The four gastric carcinoma-derived EBV (GC-EBV) were all type I. Compared with the reference EBV genome, a total of 1815 SNPs (146 indels), 1519 SNPs (106 indels), 1812 SNPs (126 indels) and 1484 SNPs (106 indels) were found in GDGC1, GDGC2, YCCEL1 and SNU-719, respectively. These variations were distributed across the entire genome, especially in latent genes. In contrast, the sequences of promoters and non-coding RNAs were strictly conserved. Phylogenetic analyses suggested the presence of at least two parental lineages of EBV among the GC-EBV genomes. Rates of protein evolution analyses showed that lytic genes were under purifying selection; in contrast, latency genes were under positive selection. In conclusion, this study determined the EBV genomes in EBVaGC from Guangdong and performed a detailed genome-wide analysis of GC-EBV, which would be helpful for further understanding of the relationship between EBV genomic variation and EBVaGC carcinogenesis.
INTRODUCTION
Epstein-Barr virus (EBV) is a ubiquitous gamma-herpesvirus that infects over 90 % of adults worldwide; it is a dsDNA virus whose genome is around 170 kb. It is classified as types 1 and 2 EBV, based on sequence variation in the EBNA-2 and EBNA-3 genes. Type 1 EBV strain is more prevalent and has a greater cell-immortalizing capacity than type 2 [1] . EBV is associated with several malignant neoplasms, including Burkitt's lymphoma (BL), Hodgkin's lymphoma, nasopharyngeal carcinoma (NPC) and a subset of gastric carcinoma defined as EBV-associated gastric carcinoma (EBVaGC) [2] . Among these EBV-associated neoplasms, EBVaGC is the most prevalent. The annual global incidence of gastric carcinoma is over 950 000 cases [3] ; hence, over 90 000 patients (~10 % of gastric carcinomas) worldwide are estimated to develop EBVaGC annually, which is more than that for NPC (60 000 new cases per year) and BL (10 000 new cases per year) [4] .
Although EBV is ubiquitous, it causes different diseases in different populations. For example, NPC is much more prevalent in southern China while BL is found most commonly in equatorial Africa [2] . Many factors, including difference in genetic background between populations and environmental factors, are proposed as contributing to the varying incidence of EBV-associated diseases in different geographic populations [2] ; however, the possibility of the existence of highly tumorigenic EBV strains and/or diseaseassociated EBV variants cannot be excluded.
To investigate the role of EBV sequence variation in the pathogenesis of EBV-associated malignancies, genetic variations in certain genotyping polymorphic regions in the EBV genome, such as LMP-1, EBNA-1, BZLF-1 and so on, were investigated and characterized [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . Lung et al. found that the 'f' variant, which is characterized by the presence of an additional BamHI restriction site at the BamHI-F region, was predominant in NPC and was strongly associated with NPC in Guangzhou [10, 11] . The prevalence of the 30 bp deletion in LMP-1 was relatively higher in NPC than that in healthy individuals in China [5] . The frequent association of a deletion LMP-1 variant Asp335 with NPC in Hong Kong was also reported [12] . A specific EBNA-1 subtype (V-val) was detected in diseased and healthy samples exclusively in Asia, while the V-leu subtype showed preferential occurrence in Africa and South America with BL [6, 13, 14] . In our previous study [15] , we showed that the predominant EBV variant of EBVaGC in Guangzhou was prototype F, which is different from that ('f' variant) in NPC in the same area. Moreover, a new identified variant, mut-W1/I1variant, which shows a T to C mutation at position 148 972 (wildtype EBV coordinates), was found in the majority of EBVaGCs in Guangzhou [15] . These findings provide evidence that there may be some disease-related EBV variants.
However, studies conducted to date have focused on different regions of EBV in various areas with different disease status, making comparisons across studies difficult and limiting our ability to assess the geographical distribution of EBV variants and their precise association with disease. Thus, it seems that whole-genome sequencing and genomewide comparison of variations in EBV genomes isolated from diseased and healthy subjects are needed to determine the role of EBV genomic variations in the pathogenesis of disease.
The first complete EBV genome sequence is B95.8, which was published in 1984 [16] . It was derived from an American patient with infectious mononucleosis [16] . To date, Fig. 1 . EBER-1 in situ hybridization assays on gastric carcinoma tissues confirm Epstein-Barr virus (EBV) infection in gastric carcinoma. EBV-encoded RNA 1 (EBER1) in situ hybridization (ISH) assays were performed on gastric carcinoma tissue sections of GDGC1 (a, c) and GDGC2 (b, d). EBER1 ISH-positive signals (dark brown) were found in the nuclei of the carcinoma cells but not in the non-neoplastic gastric mucosa and tumour-infiltrating inflammatory cells. (a, b: HE staining; c, d: EBER ISH; original magnification Â200; bar=100 µm).
over 100 EBV whole-genome sequences have been reported [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] . Among these, there are two EBV genomes (GD1 and GD2) derived from NPC patients in Guangdong, southern China, where NPC is endemic [21, 22, 30] . However, no complete EBV genome sequence derived from EBVaGC from Guangdong, southern China, is yet available.
To date, 11 EBV genomes derived from EBVaGC have been sequenced, which included two genomes from EBVaGC cell lines from Korea (YCCEL1 and SNU-719) [26, 27] and nine from primary EBVaGC biopsy specimens from northern China (EBVaGC1-9) [28] . These EBVaGC-derived EBV genomes were all from non-endemic area of NPC.
In the present study, two EBV genome sequences from EBVaGC specimens from Guangdong (designated as GDGC1 and GDGC2) were determined by next-generation sequencing, de novo assembly and joining of contigs by Sanger sequencing. In addition, we also sequenced EBV from two Korean EBVaGC cell lines, YCCEL1 and SNU-719. Genomic diversity, including single nucleotide polymorphisms (SNPs) and insertions and deletions (indels), phylogenetic analyses and rates of protein evolution, were performed by bioinformatics softwares.
RESULTS

Determinaton of EBV genomes
The two gastric carcinoma cases were EBVaGC, as these both exhibited EBER-1 ISH-positive signals restricted to the nuclei of carcinoma cells (Fig. 1) . DNAs isolated from these two EBVaGCs (GDGC1 and GDGC2) and two EBVaGC cell lines (YCCEL1 and SNU-719) were subjected to genomic sequencing and assembly. The detailed information of the sequencing data is summarized in Table 1 . For assembly, the de novo approach was used. One copy of internal repeat 1 (IR1), IR2, IR4 and the terminal repeats (TR) were sequenced by next-generation sequencing (NGS), whilst the number of repeats was adopted in our assembly. We used the same number of repeats as that of the reference EBV genome. Details of the contig data are listed in Table S1 (available in the online version of this article). The genome sizes, estimated based on the reference EBV genome sequence, were as follows: GDGC1 (169 611 bp), GDGC2 (171 299 bp), YCCEL1 (169 122 bp) and SNU-719 (170 379 bp).
For validation, we found that the sequences of EBV fragments (EBNA-1, LMP-1 and BBLF-4) determined by NGS and conventional Sanger sequencing were identical, suggesting that the confidence level for the assembly results was high. In addition, our re-sequenced YCCEL1 genome has 100 % identity with the previous one. For SNU-719, the identity of our sequence with the previous one was 99.08 %. Mismatch base accounted for 0.14 % (245 bp), while insertion and deletion bases accounted for 0.48 % (827 bp) and 0.28 % (487 bp), respectively. Fig. S1 shows the synteny analysis results.
Analysis of EBV genome heterogeneity
In GDGC1, we found a total of 16 heterogenous sites within the viral genome, three of which were located in the coding region while the remainder were located in intergenic regions. For GDGC2, we found 10 heterogenous nucleotide positions, all of which were located in the coding region. YCCEL1 had four heterogenous sites, one of which was located in BLLF1 while the remainder were located in intergenic regions. In contrast, no heterogenous sites were found in the SNU-719 EBV genome (Table S2 ).
Global comparison of EBV genomes
Global comparison of EBV genomes showed that these generally have high sequence identity, except for repeat regions and polymorphic regions spanning EBNA-2, EBNA-3A, -3B and -3C (Fig. 2) . Overall sequence similarities between the four strains and the reference EBV genome sequence were high, reaching 98.87 % (GDGC1), 98.16 % (GDGC2), 98.58 % (SNU-719) and 98.74 % (YCCEL1), respectively.
The four GC-EBV sequences are type 1 EBV EBV is classified as types 1 and 2, based on sequence variation in the EBNA-2 and EBNA-3 genes [1] . The identities of the four GC-EBV sequences with type 1 EBV (B95.8/Raji) in EBNA-2 were 98.04~99.68 %, while those in EBNA-3A were 98.63~99.17 %, in EBNA-3B 98.51~99.43 %, in EBNA-3C 99.01~99.45 %. However, the identities of the four GC-EBV sequences with type 2 EBV (AG876) in EBNA-2, EBNA-3A, -3B and -3C were 80.94~84.08 %, 91.94~92.12 %, 89.36~89.47 % and 91.08~91.94 %, respectively. A Genome Browser snapshot of the reads from the four GC-EBV sequences aligned against type 1 and type 2 reference EBV genomes showed that there were large regions with no coverage in the EBNA-3 region, which was used to discriminate EBV type 1 from type 2, in the type 2 mappings but not in the type 1 mappings (Fig. S2 ). These findings demonstrated that the four GC-EBV sequences are type 1 EBV. (Table S4 ). In regard to individual genes, the largest proportion of shared SNPs is located in EBNA-LP (58/495), followed by LF3 (53/495), LMP1 (42/495) and BPLF1 (28/495) (Table S5) .
To explore the possible association between EBV variations and disease or geography, we compared the shared variations among different tumours in the same area (GDGC1 and GDGC2 vs. GD1, GD2, C666-1, HKNPC1-9 and M81; Tables S6 and S7) or the same tumours in different areas (GDGC1 and GDGC2 vs YCCEL1 and SNU-719; Tables S8  and S9; GDGC1 and GDGC2 vs EBVaGC1-9; Tables S10  and S11 ). Generally, a large proportion of shared variations in coding regions was located in latent proteins, and both geographically and disease-associated EBV variations were found.
Finally, we sorted out the variations that were shared by EBVaGC-derived EBV strains, which included GDGC1, GDGC2, YCCEL1, SNU-719 and EBVaGC1-9. In total, EBVaGC-derived EBV sequences shared 461 SNPs and three indels. Among these, 111 SNPs and three indels were located in non-coding regions while 350 SNPs were located in coding regions, 157 of which were non-synonymous Pair-wise alignment of GDGC1, GDGC2, YCCEL1, SNU-719 and AG876 with the reference EBV genome. The four GC-EBV genomes (GDGC1, GDGC2, YCCEL1 and SNU-719) generally had high sequences identity with the reference EBV genome, except for the sequences in the OriP repeat region and polymorphic genes, such as EBNA-2 and EBNA-3. AG876 (type 2 EBV) served as a control, which showed lower sequence identity in genes EBNA-2 and -3 than the four GC-EBV genomes (type 1 EBV). The figure was generated by mVISTA software, using a 100 bp moving window with a minimum identity of 50 % and maximum identity of 100 %. Repeat regions are shown in pale green, while latent genes are shown in blue.
SNPs. The distribution of the shared SNPs in coding regions is shown in Table S12 .
Amino acid changes in CD8 + and CD4 + T-cell epitopes of EBNA-1, -2, -3A, -3B and -3C proteins The amino acid variations in CD8 + and CD4 + T-cell epitopes of EBNA-1, -2, -3A, -3B and -3C among the four GC-EBV genomes are summarized in Tables 3 and 4 , respectively. We found that certain epitopes were conversed among the four GC-EBV genomes, while others were found to be changed. In total, for CD8 + epitopes, five (5/7) of EBNA-1, zero (0/6) of EBNA-2, four (4/14) of EBNA-3A, four (4/8) of EBNA-3B and three (3/9) of EBNA-3C were found to have amino acid changes (Table 3) . For CD4+ epitopes, amino acid changes were found in 13 (13/17) of EBNA-1, zero (0/6) of EBNA-2, three (3/4) of EBNA-3A, one (1/3) of EBNA-3B and five (5/12) of EBNA-3C (Table 4) .
Variations in promoter sequences: Cp, Qp, Fp, LMP1p and LMP2Ap
In the present study, we observed variations in Cp, Qp, Fp, LMP1p and LMP2Ap in genomes GDGC1, GDGC2, YCCEL1 and SNU-719 EBV. Wp sequence variations could not be observed because this is located in the 3 kb major internal repeat, whose sequences were not determined clearly. Compared to the reference EBV genome, all these promoter sequences were generally highly conserved. The sequence identity of these promoter sequences ranged from 91.4 to 99.3 %.
Cp had 10 point mutations (coordinates 10 624 G>T, 10 726 T>C, 10 751 T>C, 10 802 G>T, 10 841 A>C, 10 906 C>T, 10 927 G>T, 10 936 T>C, 11 040 A>C, 11 325 G>T) and two indels (a C deletion at coordinate 10 785 and a C insert at coordinate 10,798) in its 808 nucleotides, all of which were shared by the four GC-EBV genomes. Qp had two point mutations (coordinates 49 937 G>A and 50 134 G>C) in its 301 nucleotides. Coordinate 49 937 G>A was found in the four GC-EBV sequences, while coordinate 50 134 G>C was detected only in GDGC1. 
Variations in non-coding RNAs
In addition to coding RNAs that can translate into proteins, EBV produces ncRNAs, including EBER1, EBER2 and ebvmiRNAs. We analysed sequence variations of these ncRNAs ofromthe four GC-EBV sequences and found that all were generally highly conserved (Table S13 ). The average pairwise sequence identity (APSI) of these ncRNAs ranged from 98.20 to 100 %.
Specifically, EBER1 did not contain any mutations while EBER2 contained six mutations, five of which (6999 T>G, 7001 A>T, 7012 A>G, 7016 A>T and 7048 A>C) were found in GDGC1 and the other one was in YCCEL1 (6981 C>A). For ebv-miRNAs, we found a C-to-T mutation in ebv-miR-BART8, a G-to-A mutation in ebv-miR-BART10, a C-to-T mutation in ebv-miR-BART11, a C-to-G mutation in ebvmiR-BART12, a C-to-T mutation in ebv-miR-BART17, a Tto-C mutation, a G-to-A mutation and a T-to-C mutation in ebv-miR-BART19, and a G-to-A mutation in ebv-miR-BHRF1-3.
Phylogenetic analysis of EBV genomes
Phylogenetic analyses based on whole-genome alignment of EBV genomes revealed that the four GC-EBV genomes clustered closely with other EBV genomes derived from Asia, which were segregated from EBV genomes derived from other areas of the world (Fig. 4) . Phylogenetic analyses based on type-independent genes, including EBNA-1, LMP-1, LMP-2, BLLF-1 and BZLF-1, also showed that the EBV sequences generally clustered in a manner consistent with geographical location (Fig. S4) . However, based on EBNA-3A, -3B and -3C, the four GC-EBV genomes clustered with other type 1 EBV sequences but were clearly segregated from the type 2 EBV sequences (Fig. S4) , indicating that the four GC-EBV sequences are type 1. In addition, in most phylogenetic trees derived from specific EBV-encoded gene, The aligned genomes include GDGC1, GDGC2, YCCEL1 and SNU-719.
B95-8/Raji EBV sequence was used as the reference genome. GDGC1 and GD2 clustered closely, while GDGC2, YCCEL1, SNU-719 and GD1 clustered closely (Fig. S4) , suggesting the presence of at least two parental lineages of EBV among the GC-EBV genomes.
Rates of protein evolution
Using the multiple sequence alignments of our four GC-EBV sequences plus 21 additional EBV sequences (AG876, Akata, C666-1, GD1, GD2, HKNPC1-9, K4123-Mi, K4413-Mi, Mutu, NA12874, NA19114, NA19315 and NA19384), we calculated ! (the dN/dS ratio) for all coding regions by means of PAML's codeml. The average ! value for lytic genes was 0.36, which indicates purifying selection. In contrast, ! was significantly increased in latency genes, with an average of 1.23 (Wilcoxon-test P-value 0.0002362), which indicates positive selection.
In order to identify particular genes under strong purifying selection, we fixed ! at 0.36 (the average ! value for lytic genes) obtaining a second likelihood value. Genes whose ! values were significantly lower than 0.36 were regarded under strong purifying selection. A total of 28 genes were found under strong purifying selection, as indicated by their significantly lower ! values (Table S14) .
We then repeated the codeml Model 0 analysis fixing ! as 1 (the expected value of ! under neutrality). EBNA-1, which encodes the essential protein for the establishment and maintenance of EBV latency, and RPMS1 yielded ! values significantly greater than 1 (!=4.43 and 8.38, respectively), indicating that EBNA-1 and RPMS1 were under strong positive selection.
DISCUSSION
In the present study, NGS was employed to determine the EBV genomes from EBVaGC tissues and cell lines. Compared with the first-generation sequencing method, NGS is rapid and cost-effective. Only a small amount of DNA is needed to yield sufficient data for subsequent analysis. In this study, a total of 18.5, 16.6, 22.6 and 20.7 Gb reads were generated from samples GDGC1, GDGC2, YCCEL1 and SNU-719, respectively. Due to the presence of the much more abundant cellular genomic DNA in the DNA preparations, the number of reads belonging to EBV was low, accounting for only 0.02~0.23 % of the total reads. However, since the original data were sufficient, the average sequencing depth for genomes GDGC1, GDGC2, YCCEL1 and SNU-719 was~73Â,~24Â,~300Â and~250Â, respectively, which was sufficient for further analysis.
To validate the accuracy of NGS results, three EBV fragments (i.e. EBNA-1, LMP-1 and BBLF-4) were amplified and sequenced using conventional Sanger sequencing. This showed that the sequences thus determined were identical to those determined by NGS, indicating that the confidence level for NGS was very high. In addition, we found that our re-sequenced YCCEL1 and SNU-719 genomes had 100 and 99.08 % identity, respectively, with previously published sequences [26, 27] . The low number of discrepancies between our SNU-719 sequence and those above may have been due to sequencing errors and spontaneous mutations during prolonged cell culture [27] . Thus, these data suggest that the NGS results are reliable.
Relative to conventional Sanger sequencing, one advantage of NGS-based viral genome assembly is the good coverage depth arising from the sequencing of multiple genome fragments. This allows us to assess potential heterogeneity in genome populations by analysing nucleotide composition at each position along the genome [18] . In the present study, the heterogeneity of the four GC-EBV genomes ranged from 0 % (SNU-719) to 0.009 % (GDGC1), which was much lower than the inter-strain variability of~0.5 % for viruses of the same type [25] , indicating that heterogeneity is unlikely to be the result of co-infection of different viral strains. In other words, it suggested that only a single virus strain occurred in the tumour tissue or cell line. This, to some extent, is another piece of evidence to support the current view of clonal expansion in EBVaGC.
Both the global comparison and pairwise alignment of the four GC-EBV genomes against the reference EBV genome showed that the EBV genomes were generally similar to each other, with overall sequence similarity ranging from 98.16 to 98.87 %. Consistent with this finding, the mutation 
976,K>E YCCEL1
The aligned genomes include GDGC1, GDGC2, YCCEL1 and SNU-719.
B95-8/Raji EBV sequence was used as the reference genome.
'#' indicates that there is considerable variation in this epitope among the aligned EBV genomes.
rates of the four GC-EBV genomes were low (from 0.93 to 1.16 %) when compared to the reference EBV genome.
Regarding the distribution of mutations, we noted that nucleotide diversity was observed across the entire genome. The EBNA-2, -3A, -3B and -3C genes were the major regions with a number of variations. As is known, EBV is classified as types 1 and 2 based primarily on the sequence of their EBNA2 and EBNA3 genes [2] . In the present study, the identities of the four GC-EBV sequences with type 1 EBV (B95.8/Raji) in EBNA-2, EBNA-3A, -3B and -3C were 98.04~99.68 %, while those with type 2 EBV (AG876) were lower, at 80.94~92.12 %. In addition, phylogenetic analyses based on EBNA-3A, -3B and -3C showed that the four GC-EBV genomes clustered with other type 1 EBV sequences but clearly segregated from the type 2 EBV sequences. These results demonstrated that the four GC-EBV sequences are all type 1 EBV.
In addition to EBNA-2 and EBNA-3s, other latent proteins also harbour variations. In Palser et al.'s study [26] and our previous study [32] , it was demonstrated that SNP density was highest in latency-associated genes. Latent EBV infection has a substantial role in causing many human malignant tumours [1] . Latent proteins are the limited viralencoded proteins expressed during EBV latency [33] . In protein evolution analysis, the overall ! value (the dN/dS ratio) for latency proteins was higher than 1, indicating that the latency proteins were generally under positive selection. When EBV co-evolves with a host, under positive selection imposed by the host, EBV tends to generate variations in order to escape host immunosurveillance [34, 35] . Thus, it is not surprising that we observed a higher SNP density in latent genes.
In contrast to the frequent mutations that occurred in latent genes, the sequences of promoters and ncRNAs were strictly conserved. A few point mutations were found in the sequences of Cp, Qp, Fp and LMP2Ap, and only scattered mutations could be identified in certain ncRNA sequences. Our previous study also showed that the sequences of promoters and ncRNAs were strictly conserved among 22 EBV genomes from diseased and healthy individuals [32] . Promoters and EBV-generated ncRNAs play important roles in regulating viral processes and in mediating host-virus interactions [36, 37] . Thus, the conservation of promoter sequences and EBV-generated ncRNAs suggests that they play important roles in the EBV life cycle.
In summary, the present study for the first time determined EBV genome sequences in EBVaGC from Guangdong, an endemic area of NPC, and performed a genome-wide analysis of GC-EBV genomes. We found that the two EBV genomes from EBVaGC in Guangdong were all type 1 EBV, and were generally highly similar to other EBV genomes at the genome level. However, a degree of genetic diversity weas detected across the entire genome, especially in the latent genes. In contrast, the sequences of promoters and non-coding RNAs were strictly conserved. These findings suggested that both latent genes and non-coding RNAs play important roles in the EBV life cycle. This will be helpful towards further understanding of the relationship between EBV genomic variation and EBVaGC carcinogenesis.
METHODS
EBVaGC specimens
Two fresh tissue specimens from primary EBVaGC were obtained from gastric carcinoma patients who underwent surgery at The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, between 2011 and 2012. EBV-encoded small RNA 1 (EBER-1) in situ hybridization assay was performed on their corresponding formalin-fixed, paraffin-embedded specimens to confirm EBV infection. The first patient (Guangdong gastric carcinoma patient #1, GDGC1) was a 54-year-old male whose diagnosis was moderately differentiated gastric adenocarcinoma (intestinal-type gastric carcinoma according to the Lauren classification). The second patient (Guangdong gastric carcinoma patient #2, GDGC2) was a 58-year-old male whose diagnosis was poorly differentiated gastric adenocarcinoma (diffuse-type gastric carcinoma according to the Lauren classification). Both tumours were located in the body of the stomach. The clinical stages of GDGC1 and GDGC2 were determined to be T4N2M1 (Stage IV) and T3N0M0 (Stage IIb), respectively. Neither of the patients had received preoperative chemotherapy or radiotherapy.
EBVaGC cell lines
Two human EBVaGC cell lines, YCCEL1 and SNU-719, were used in the present study [38, 39] . YCCEL1 was established from the ascitic fluid of a pathologically proven gastric carcinoma patient, a 64-year-old Korean male with advanced gastric cancer accompanied by carcinomatosis, and the primary biopsy taken from the stomach showed a poorly differentiated adenocarcinoma [38] . The SNU-719 cell line was established from primary culture of the tumour tissue of a pathologically proven gastric carcinoma patient, a 53-year-old Korean male. The tumour in his stomach was a moderately differentiated adenocarcinoma [40] .
The YCCEL1 cell line was kindly provided by Prof. Qian Tao, while the SNU-719 line was purchased from the Korean Cell Line Bank, Seoul, Korea. The two cell lines were cultured in RPMI-1640 medium (Gibco, USA) supplemented with 10 % fetal bovine serum (FBS; Gibco, USA), and were maintained in a 37 C humidified incubator containing 95 % air and 5 % CO 2 . Cells were passaged as needed just before confluence and detached by brief trypsin treatment.
Genomic DNA extraction DNA was extracted from tumour specimens and cell lines using the Omega tissue DNA kit (Omega, GA, USA) according to the manufacturer's protocol. DNA concentrations were determined using a Nano-Drop 2000 spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA). Non-degraded DNA with an A 260 /A 280 ratio between 1.8 and 2.0 was used for the subsequent sequencing experiments.
DNA whole-genomic library construction and nextgeneration DNA sequencing DNA whole-genomic libraries were prepared using the Illumina Truseq DNA sample preparation protocol. In brief, 2-6 µg genomic DNA was sheared to generate about 300-500 bp fragments. These fragments were subsequently endblunted, 'A'-tailed, adaptor-ligated and enriched by 14 cycles of PCR to generate libraries for sequencing. Libraries were quantified and sequenced for paired-end 125 bp using the Illumina HiSeq 2000 instrument (Illumina Inc., San Diego, CA, USA). The final size of the fragments used for sequencing was around 300-500 bp.
De novo assembly of EBV genomes Raw sequencing data generated by the Illumina Hiseq 2000 instrument were first processed for quality assessment using Illumina's default parameters to remove reads of low quality or those comprised of adaptor or homopolymer sequences. The high-quality reads were then aligned to human (hg19) by the use of SOAPaligner (Version 2.21) [41] and Burrows-Wheeler Aligner (BWA, Version 0.7.5a) [42] . After human sequences were removed, the remaining reads were subjected to de novo contig assembly by using CLC Genomics Workbench with the default parameters (http://www. clcbio.com, version 7.0.4). The location and orientation of contigs were evaluated by pairwise alignment of these to the reference EBV genome (B95.8/Raji, EBV-wild type, Accession No.: NC_007605) [16, 43] . Poorly aligned and/or questionable regions (including certain repeat regions), as well as the gaps between the contigs, were further analysed by polymerase chain reaction (PCR) and Sanger sequencing. The primers used in the present study are listed in Table S1 . PCR was performed with 2 µl of DNA in a 50 µl total reaction mixture containing 10 mM Tris-HCl (pH 8.0), 50 mM KCl, 1.5 mM MgCl 2 , 200 mM dNTP, 0.5 mM of each primer and 1.25 U Taq Polymerase (TaKaRa, Dalian, China). The amplification profile was 35 cycles of denaturing at 95 C, annealing at 50 C and extension at 72 C. The sequences of PCR products were then determined using an ABI Prism BigDye Terminator cycle sequencing kit (Applied Biosystems, USA) in the ABI Prism 3730 DNA sequencer (Applied Biosystems, USA). After the Sanger-solved regions were introduced into the assembled genomes, they were then inspected again by alignment with the raw sequencing reads. Finally, the unsolved gaps were filled with tracts of 'N' of length estimated based on the EBV reference genome.
The work-flow for EBV whole genome sequencing is summarized in Fig. S1 .
Sequence validation
To validate the accuracy of the EBV assembly based on the NGS reads, three EBV gene fragments (i.e. EBNA1, LMP1 and BBLF4) were amplified by PCR and sequenced using conventional Sanger sequencing. The primer pairs are shown in Table S1 . The amplification and sequencing protocol was the same as that mentioned above.
Heterogeneity analysis
Relative to conventional Sanger sequencing, one advantage of NGS-based viral genome assembly is its good coverage depth arising from the sequencing of multiple genome fragments. This allows us to assess possible heterogeneity in genome populations by analysing the nucleotide composition at each position along the genome [18] . According to Kwok et al.'s studies [23, 25] , a position was defined to be homogeneous when the variant frequency is !95 % and a position to be heterogeneous when the variant frequency is between 20 and 94 %,;both homogenous and heterogeneous positions require a read depth of 5 or above.
Comparative analysis and identification of variations A global comparison and visualization of five EBV genome sequences (GDGC1, GDGC2, YCCEL1, SNU-719 and AG876) against the reference EBV genome sequence (B95-8/Raji, Accession No.: NC_007605) [16, 43] was performed using the mVISTA program (http://genome.lbl.gov/vista/ mvista/submit.shtml) with a 100 bp moving window. AG876 is a complete type 2 EBV sequence [17] which serves as a control. The region (13-42 kb) with highly repetitive sequences in the EBV genome where the majority of gaps and ambiguity reads occurred was not included for the genomic comparison.
Since the YCCEL1 and SNU-719 EBV genome sequences have previously been reported by Song et al. [27] and Palser et al. [26] , respectively, we also compared our sequences with the published sequences using Geneious software (version 8.1.5). Internal repeats, terminal repeats and areas corresponding to 'N' in EBV genomes were not compared in the pairwise comparison.
Lists of single nucleotide polymorphisms (SNPs), insertions and deletions (indels) were generated from pairwise comparison of the four gastric carcinoma-derived EBV (GC-EBV) genome sequences against the reference EBV genome, NC_007605, using LASTZ software (version 1.02.00) [44] . Substitutions, insertions and deletions were all considered as variations. We used Circos plot software [45] to show genome-wide variation diversity in the four GC-EBV genomes. The variations identified in the major repeats, including internal repeats (IR) 1 to 4, terminal repeats (TR) and a family of repeats (FR), were disregarded. Positions without sequence data or those marked with 'N' were also not included in the mutation analysis. Particular attention was paid to the non-coding RNAs, the promotors and encoding region of a protein. Those resulting in amino acid changes in known CD4 + and CD8 + T-cell epitopes were of most interest to us.
In addition, the SNPs and indels found in EBV genomes derived from NPC in southern China (GD1, GD2, C666-1, HKNPC1-9 and M81), as well as EBV genomes derived from EBVaGC patients from northern China (EBVaGC1-9), were also generated and compared with those found in the four new GC-EBV sequences (GDGC1, GDGC2, YCCEL1 and SNU-719). Comparisons were focused on shared variations between the same tumours in different areas (GDGC1 and GDGC2 vs. YCCEL1 and SNU-719 vs. EBVaGC1-9), or different tumours in the same area (GDGC1 and GDGC2 vs. GD1, GD2, C666-1, HKNPC1-9 and M81).
Phylogenetic analysis
To date, more than 100 EBV whole-genome sequences have been reported [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] , including the reference EBV genome sequence (B95-8/Raji, Accession number: NC_007605) and EBV genomes from different diseases and healthy individuals. The EBV genome sequences, except NA12878, NA19114, NA19315 and NA19384, were retrieved from the Genbank database. GenBank files contain annotation and genome sequences. NA12878 was kindly provided by Professor Shyh-Ching Lo, and sequences NA19114, NA19315 and NA19384 were acquired from supplementary materials from the article 'Genome-Wide Analysis of Wild-Type Epstein-Barr Virus Genomes Derived from Healthy Individuals of the 1000 Genomes Project' [20] . Information on EBV genome sequences, including their accession numbers, is summarized in Table S2 .
The global sequence alignments of the EBV genomes (including both published and new sequences) and individual gene sequence alignments were analysed using MUGSY software (version 1.0) [46] . The alignments were used to generate phylogenetic trees with the maximum likelihood (ML) algorithrm.
Rates of protein evolution analysis
In order to test whether EBV genes show different patterns of molecular evolution, we usedMUSCLE(v3.8.31) [47] software to perform multiple alignment for each gene. We performed dN/dS analysis using Model 0 in codeml from PAML [48] , which gives one omega (!) ratio for all lineages considering the global tree resulting from the alignment of the whole EBV sequences. The NSites parameter, which sets variation between sites, was used (NSites=0).
We also studied dN/dS (! ratio) at the individual gene level in order to identify particular genes under strong purifying or positive selection. In general, genes that are very conserved at the protein sequence level tend to be considered under strong purifying selection, while, in contrast, genes with relatively larger rates of non-synonymous than synonymous changes are considered under strong positive selection [20] . Thus, we fixed ! at 0.36 (the average ! value for lytic genes) or 1.0 (the expected value of ! under neutrality) to obtain a second likelihood value, also under Model 0. NSites 0 versus NSites 0 fixing ! at 0.36 or 1.0 was compared with a log likelihood test, with one degree of freedom. We performed multiple test correction with a FDR q-value cut-off of 5 %. The genes whose ! values were significantly lower than 0.36 were considered under strong purifying selection, while those whose ! values were significantly greater than 1.0 were considered under strong positive selection.
Accession numbers
Sequence data for the four GC-EBV genomes (GDGC1, GDGC2, SNU-719 and YCCEL1) have been submitted to GenBank. The accession numbers are as follows: KX674064 (GDGC1), KX674065 (GDGC2), KX674066 (SNU-719), and KX674067 (YCCEL1). Raw sequencing data were also deposited in the Sequence Read Archive of NCBI (study accession number PRJNA317709).
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